PRESTIGE CONSUMER HEALTHCARE INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.10% for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-05-14
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2026 was -0.10%.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was 0.00%.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 0.00%, a 100.00% decline from fiscal 2017.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was 0.30%, a 40.00% decline from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2026-03-31 | -0.10% 10-K · filed 2026-05-14 |
| 2019-03-31 | 0.00% 10-K · filed 2019-05-13 |
| 2018-03-31 | 0.00% 10-K · filed 2019-05-13 |
| 2017-03-31 | 0.30% 10-K · filed 2019-05-13 |
| 2016-03-31 | 0.50% 10-K · filed 2018-05-10 |
| 2015-03-31 | 0.40% 10-K · filed 2017-05-17 |
| 2014-03-31 | 1.00% 10-K · filed 2016-05-17 |
| 2013-03-31 | 1.60% 10-K · filed 2015-05-14 |
| 2012-03-31 | 2.10% 10-K · filed 2014-05-19 |
| 2011-03-31 | 0.00% 10-K · filed 2013-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |